Abstract: Methods are provided for treating a subject with an anti-CD47 agent.

Abstract: Example posture analysis systems and methods are described. In one implementation, a computing system identifies a deviation of a user's posture from a predetermined posture based on visual data associated with the user. The user is informed of the deviation via a graphical image displayed on a display device. The user is then provided with instructions for correcting the deviation via the graphical image displayed on the display device.

Abstract: A substance processing system includes a pressurizer configured to pressurize air and a processing chamber configured to process a substance. The system also includes a heat exchanger coupled between the pressurizer and the processing chamber. A nozzle is coupled to the processing chamber such that output from the nozzle comprises a substantially even pressure distribution.

Abstract: A semiconductor device includes a contact metallization layer that includes aluminum and is arranged on a semiconductor substrate, an inorganic passivation structure arranged on the semiconductor substrate, an organic passivation layer comprising a first part that is arranged on the contact metallization layer, and a second part that is arranged on the inorganic passivation structure, a first layer structure including a first part that is in contact with the contact metallization layer, a second part that is contact with the inorganic passivation structure, and a third part that is disposed on the semiconductor substrate laterally between the inorganic passivation structure and the organic passivation layer.

Abstract: An oxygen evolution reaction catalyst includes iridium oxide that exhibits a weight loss of less than 1% by weight upon exposure of the oxygen evolution reaction catalyst to a 3.3 vol % hydrogen stream in argon at a temperature of 80° C. for 12 hours and has a BET specific surface area of more than 15 m2/g.

Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of diseases such as liver disease.

Abstract: A catalyst-coated membrane includes a proton-exchange membrane, an anode applied to a first side of the membrane, including at least one noble-metal-containing catalyst, an areal weight of the noble-metal-containing catalyst, based on the noble metal content, being less than or equal to 0.6 mg/cm2, and a cathode applied to a second side of the membrane, wherein an areal expansion of the catalyst-coated membrane is less than 20% after being held for two hours in water heated to 100° C.

Abstract: Provided herein are signal-regulatory protein ? (SIRP?) fusion polypeptides comprising modified Fc domains, and methods of making and use thereof. The inclusion of the modified Fc domains results in pharmacokinetic and/or phamacodynamic improvements to the SIRP? fusion polypeptides. The compositions and methods described herein may be used to treat a variety of diseases, such as cardiovascular disease.

Abstract: A fuel cell membrane-electrode assembly includes a support material including a ceramic material and iridium oxide, wherein a weight fraction of iridium oxide, based on metallic iridium, with respect to the total weight of the support material, is at most 50 wt%, and the support material has a weight loss of less than 3 wt%, based on the weight fraction of the iridium oxide on exposure of the support material to a 3.3 vol% hydrogen stream in argon at a temperature of 80° C. for 12 hours.

Abstract: Methods, kits, and compositions are provided herein that can be used to treat ovarian cancer using an anti-CD47 antibody. The anti-CD47 antibody can be used alone or in combination with one or more additional agent such as chemotherapy.

Abstract: A wide band gap semiconductor device includes a semiconductor body having a first surface and a second surface opposite to the first surface along a vertical direction. The semiconductor device further includes a first region of a first conductivity type adjoining at least partially the first surface, a drift region of a second conductivity type, a highly doped second region adjoining the second surface, and a buffer region of the second conductivity type arranged between the drift region and the highly doped second region. A vertical profile of a doping concentration of the buffer region includes at least one step in a first section and is increasing approximately exponentially toward the second surface in a second section. The first section is arranged between the second section and the highly doped second region.

Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.

Abstract: An apparatus and method of using the same for simulating surfing skateboarding, snowboarding or the like. The apparatus comprises a platform capable of supporting a user such as a continuous elastic surface such as trampoline or similar. A support is coupled to the platform for holding the platform. The apparatus further comprises a bearing or similar assembly coupled to the support for allowing the platform to rotate about an axis which is displaced a distance from the user while standing atop the platform during simulation thus simulating bottom and top turns. The apparatus further comprises a stand coupled to the bearing for securely supporting the bearing and tilting the axis of rotation.

Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD4 7 blockade.

Abstract: Disclosed is a method that includes: measuring at least one characteristic of a superjunction region of a SiC superjunction device, wherein the superjunction region is arranged in a semiconductor body and comprises a plurality of first regions of a first doping type and a plurality of second regions of a second doping type complementary to the first doping type; and generating dopant like defects of one doping type in the superjunction region in a doping process. At least one parameter of the doping process is adjusted dependent on the at least one measured characteristic. The doping process includes an implantation process in which particles are implanted into the semiconductor body to form crystal defects in the semiconductor body in the superjunction region, and an annealing process in order to form the dopant like defects based on the crystal defects.

Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell.

Abstract: An approach includes collecting metadata indicative of a computer system comprising (i) a primary database, configured to connect to a secondary database, and (ii) the secondary database that replicates the primary database. The approach further includes receiving, at the primary database from a requestor, a query referencing the primary database. The approach further includes, responsive to receiving the query, performing an offload including: determining a first load on the primary database; responsive to the first load satisfying a first offload condition, determining, using the metadata, whether a second load on the secondary database satisfies a second offload condition; and responsive to the second load satisfying the second offload condition, offloading at least part of the query to the secondary database in order to cause the at least part of the query to be executed by the secondary database. The method further includes providing to the requestor results of the query.

Abstract: Methods are provided herein for determining and administering optimized dosing of therapeutic anti-CD47 agents, in a schedule that provides safe escalation of dose while achieving a therapeutic level in a clinically effective period of time. The methods can comprise the steps of clearance, escalation, and maintenance. In one embodiment the dosing regimen administers an initial (i) sub-therapeutic dose of an anti-CD47 agent or (ii) a cytoreductive therapy to achieve a safe level of circulating tumor cells for subsequent treatment (clearance); escalating the dose of an anti-CD47 agent until a therapeutic dose is reached (escalation); and maintaining the therapeutic dose for a period of time sufficient to reduce tumor cells in the bone marrow of the patient (maintenance). In an alternative dosing regimen, a patient determined to have a safe level of circulating tumor cells at presentation is treated by the steps of escalation and maintenance without initial clearance.

Abstract: A method for improving the accuracy of a digital medical model of a part of a patient, the method includes obtaining a set of at least 2 medical images of the patient, where an element including a predefined geometry and/or predefined information was attached to the patient during the recording of the medical images; obtaining at least 2 tracking images taken with at least one camera having a known positional relationship relative to the medical imaging device, the tracking images depicting at least part of the element; determining any movement of the element between acquisition of the at least 2 tracking images; and generating the digital medical model from the acquired medical images, wherein the determined movement of the element is used to compensate for any movement of the patient between the acquisition of the medical images.